___

• Holick MF. Vitamin D deficiency. N Engl J Med. 2007; 357:266-81.
• Atli T, Gullu S, Uysal AR, Erdogan G. The prevalence of Vitamin D deficiency and effects of ultraviolet light on Vitamin D levels in elderly Turkish population. Arch Gerontol Geriatr. 2005; 40:53-60.
• Pehlivan I, Hatun S, Aydoğan M, Babaoğlu K, Gökalp AS. Maternal vitamin D deficiency and vitamin D supplementation in healthy infants. Turk J Pediatr. 2003; 45:315-20.
• Drake MT, Maurer MJ, Link BK, Habermann TM, Ansell SM, Mi- callef IN et al. Vitamin D insufficiency and prognosis in non-Hodgkin’s lymphoma. J Clin Oncol. 2010; 28:4191-8.
• Mathiasen IS, Lademann U, Jäättelä M. Apoptosis induced by vita- min D compounds in breast cancer cells is inhibited by Bcl-2 but does not involve known caspases or p53. Cancer Res. 1999; 59:4848-56.
• Naveilhan, P., Berger, F., Haddad, K., Barbot, N., Benabid, A.-L., Brachet, P., and Wion, D. Induction of glioma cell death by 1,25(OH)2 vitamin D3: towards an endocrine therapy of brain tumors. J. Neurosci. Res. 1994; 37: 2178–86.
• Vieth, R. The mechanism of vitamin D toxicity. Bone Miner. 1990; : 267–72.
• Crew KD, Shane E, Cremers S et al: High prevalence of vitamin D deficiency despite supplementation in premenopausal women with breast cancer undergoing adjuvant chemotherapy. J Clin Oncol 2009; :2151-6.
• Chen P, Hu P, Xie D, et al: Meta-analysis of vitamin D, calcium and the prevention of breast cancer. Breast Cancer Res Treat 2010; 121:469
• Gorham ED, Garland CF, Garland FC et al: Vitamin D and preven- tion of colorectal cancer. J Steroid Biochem Mol Biol 2005; 97:179-94.
• Yin L, Grandi N, Raum E et al: Meta-analysis: Longitudinal studi- es of serum vitamin D and colorectal cancer risk. Aliment Pharmacol Ther 2009; 30:113-25.
• Ng AC, Kumar SK, Rajkumar SV et al: Impact of vitamin D defi- ciency on the clinical presentationand prognosis of patients with newly diagnosed multiple myeloma. Am J Hematol 2009; 84:397-400.
• Schwartz GG. Vitamin D and intervention trials in prostate cancer: from theory to therapy. Ann Epidemiol. 2009; 19:96-102.
• Fiscella K, Winters P, Tancredi D, Hendren S, Franks P. Racial dis- parity in death from colorectal cancer: Does vitamin D deficiency cont- ribute? Cancer. 2011; 117:1061-9.
• Hanchette CL, Schwartz GG. Geographic patterns of prostate can- cer mortality: Evidence for a protective effect of ultraviolet radiation. Cancer. 1992; 70:2861–69.
• Zeleniuch-Jacquotte A, Gallicchio L, Hartmuller V, Helzlsouer KJ, McCullough ML, Setiawan VW et al. Circulating 25-hydroxyvitamin D and risk of endometrial cancer: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am J Epidemiol. 2010; 172:36-46.
• Gallicchio L, Moore LE, Stevens VL, Ahn J, Albanes D, Hartmul- ler V et al. Circulating 25-hydroxyvitamin D and risk of kidney cancer: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am J Epidemiol. 2010; 172:47-57.
• Zheng W, Danforth KN, Tworoger SS, Goodman MT, Arslan AA, Patel AV et al. Circulating 25-hydroxyvitamin D and risk of epithelial ovarian cancer: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am J Epidemiol. 2010; 172:70-80.
• Purdue MP, Freedman DM, Gapstur SM, Helzlsouer KJ, Laden F, Lim U et al. Circulating 25-hydroxyvitamin D and risk of non-hodgkin lymphoma: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am J Epidemiol. 2010; 172:58-69.
• Freedman DM, Looker AC, Abnet CC, Linet MS, Graubard BI. Se- rum 25-hydroxyvitamin D and cancer mortality in the NHANES III study (1988-2006). Cancer Res. 2010; 70:8587-97.
• Stolzenberg-Solomon RZ, Jacobs EJ, Arslan AA, Qi D, Patel AV, Helzlsouer KJ et al. Circulating 25-hydroxyvitamin D and risk of panc- reatic cancer: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am J Epidemiol. 2010; 172:81-93.
• Abnet CC, Chen Y, Chow WH, Gao YT, Helzlsouer KJ, Le Marc- hand L et al. Circulating 25-hydroxyvitamin D and risk of esophage- al and gastric cancer: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am J Epidemiol. 2010; 172:94-106.
• Harriss DJ, Atkinson G, George K, Cable NT, Reilly T, Haboubi N et al. Lifestyle factors and colorectal cancer risk (1): systematic revi- ew and meta-analysis of associations with body mass index. Colorectal Dis. 2009; 11:547-63.
• Lagunova Z, Porojnicu AC, Grant WB, Bruland Ø, Moan JE. Obe- sity and increased risk of cancer: does decrease of serum 25-hydroxyvi- tamin D level with increasing body mass index explain some of the as- sociation? Mol Nutr Food Res. 2010; 54:1127-33.
• Honma Y, Hozumi M, Abe E, Konno K, Fukushima M, Hata S, et al. a,25d Dihydroxyvitamin D3 and 1 a-hydroxyvitamin D3 prolong sur- vival time of mice inoculated with myeloid leukemia cells. Proc Natl Acad Sci U S A. 1983; 80:201–4.
• Tobler A, Koeffler HP. Differentiation of human acute myelogenc- res leukemia cells: Therapeutic possibilities. Acta Haematol. 1987; 78 (Suppl 1): 127–35.
• Osborn JL, Schwartz GG, Smith DC, Bahnson RR, Day R, Trump DL. Phase II trial of oral 1,25-Dihydroxyvitamin D (Calcitriol) in hor- mone refractory prostate cancer. Urologic Oncol. 1995; 1:195–8.
• Beer TM, Ryan CW, Venner PM, Petrylak DP, Chatta GS, et al. Do- ubleblinded randomized study of high-dose calcitriol plus docetaxel in androgen-independent prostate cancer: A report from the ASCENT in- vestigators. J Clin Oncol. 2007; 25:669–74.
• Zheng Y, Zhou H, Ooi LL, Snir AD, Dunstan CR, Seibel MJ. Vi- tamin D deficiency promotes prostate cancer growth in bone. Prostate. ; 71:1012-21.
• Ooi LL, Zhou H, Kalak R, Zheng Y, Conigrave AD, Seibel MJ, Dunstan CR. Vitamin D deficiency promotes human breast can- cer growth in a murine model of bone metastasis.Cancer Res. 2010; :1835-44.
• Berger U, Wilson P, McClelland RA, Colston K, Haussler MR, Pike JW, Coombes RC. Immunocytochemical detection of 1,25-dihydroxy- vitamin D receptors in normal human tissues. J Clin Endocrinol Metab ; 67:607–13. Dalhoff K, Dancey J, Astrup L, Skovsgaard T, Hamberg KJ, Lofts FJ et al. A phase II study of the vitamin D analogue Seocalcitol in pa- tients with inoperable hepatocellular carcinoma. Br J Cancer. 2003; :252-7.
• Miyaguchi S, Watanabe T. The role of Vitamin D3 receptor mRNA in the proliferation of hepatocellular carcinoma. Hepatogastroentero- logy 2000; 47:468–72.
• Wu FS, Zheng SS, Wu LJ, Teng LS, Ma ZM, Zhao WH, Wu W. Cal- citriol inhibits the growth of MHCC97 heptocellular cell lines by down- modulating c-met and ERK expressions. Liver Int. 2007; 27:700-7.
• Pourgholami MH, Morris DL. 1,25-Dihydroxyvitamin D3 in lipio- dol for the treatment of hepatocellular carcinoma: cellular, animal and clinical studies.J Steroid Biochem Mol Biol. 2004; 89-90:513-8.
• Jacobs ET, Thomson CA, Flatt SW, Al-Delaimy WK, Hibler EA, Jo- nes LA et al. Vitamin D and breast cancer recurrence in the Women’s Healthy Eating and Living (WHEL) Study.Am J Clin Nutr. 2011; :108-17.
• Lee MS, Huang YC, Wahlqvist ML, Wu TY, Chou YC, Wu MH et al. Vitamin d decreases risk of breast cancer in premenopausal women of normal weight in subtropical taiwan. J Epidemiol. 2011; 21:87-94.
• Kawase T, Matsuo K, Suzuki T, Hirose K, Hosono S, Watanabe M et al. Association between vitamin D and calcium intake and breast cancer risk according to menopausal status and receptor status in Japan. Can- cer Sci. 2010; 101:1234-40.
• Vashi PG, Trukova K, Lammersfeld CA, Braun DP, Gupta D. Im- pact of oral vitamin D supplementation on serum 25-hydroxyvitamin D levels in oncology. Nutr J. 2010; 9:60.
• Grau MV, Baron JA, Sandler RS, Haile RW, Beach ML, Church TR, et al. Vitamin D, calcium supplementation, and colorectal adeno- mas: results of a randomized trial. J Natl Cancer Inst 2003; 95:1765–71.
• Ahearn TU, McCullough ML, Flanders WD, Long Q, Sidelnikov E, Fedirko V et al. A randomized clinical trial of the effects of supplemen- tal calcium and vitamin D3 on markers of their metabolism in normal mucosa of colorectal adenoma patients. Cancer Res. 2011; 71:413-23.
• McCullough ML, Weinstein SJ, Freedman DM, Helzlsouer K, Flan- ders WD, Koenig K et al. Correlates of circulating 25-hydroxyvitamin D: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am J Epidemiol. 2010; 172:21-35.
• Raimondi S, Johansson H, Maisonneuve P, Gandini S. Review and meta-analysis on vitamin D receptor polymorphisms and cancer risk. Carcinogenesis. 2009; 30:1170-80.
• Köstner K, Denzer N, Müller CS, Klein R, Tilgen W, Reichrath J. The relevance of vitamin D receptor (VDR) gene polymorphisms for cancer: a review of the literature. Anticancer Res. 2009; 29:3511-36.
• Falleti E, Bitetto D, Fabris C, Cussigh A, Fontanini E, Fornasiere E et al. Vitamin D receptor gene polymorphisms and hepatocellular carci- noma in alcoholic cirrhosis. World J Gastroenterol. 2010; 16:3016-24.
• Sorumlu Yazar: Dr. Akif ALTINBAŞ Emrah Mah Göksel Sok. No:27/8 İncirli, Ankara Tel: 0 (312) 326 5795
• E-mail: drakifa@yahoo.com Grossman RI, Yousem DM. Nöroradyoloji Bilinmesi Gerekenler. 2. baskıdan çeviri. İzmir, İzmir Güven Kitabevi. 2009. p.406-407.
• Michel SJ, Given CA 2nd, Robertson WC Jr. Imaging of the brain, in- cluding diffusion-weighted imaging in methylmalonic acidemia. Pedi- atr Radiol 2004;34:580–582.
• Brismar J, Ozand PT. CT and MR of the brain in disorders of the pro- pionate and methylmalonate metabolism. AJNR 1994;15:1459–1473.
• Yesildag A, Ayata A, Baykal B, Koroglu M, Yildiz H, Oral B, Oktem F, Oyar O.Magnetic resonance imaging and diffusion-weighted ima- ging in methylmalonic acidemia. Acta Radiol 2005;46:101-3.
• Bindu PS, Kovoor JM, Christopher R. Teaching NeuroImages: MRI in methylmalonic acidemia. Neurology. 2010;74:e14.
• Okayasu I, Fujiwara M, Hara Y, Tanaka Y, Rose NR. Association of chronic lymphocytic thyroiditis and thyroid papillary carcinoma. Can- cer 1995; 76; 2312–2318.
• Fukuda A, Hirohata T, Noguchi S, Ikeda M, Matsuo K, Yoshida A. Risks for malignancies in patients with chronic thyroiditis: a long term follow-up study. Jpn. J. Cancer Res. 1987; 78; 1329–1334.
• Li Volsi VA. Papillary neoplasms of the thyroid. Pathologic and prognostic features. Am. J. Clin. Pathol. 1992; 97; 426–443.
• Tularemi. Hastalığının Kontrolü İçin Saha Rehberi. T.C. Sağlık Bakanlığı, Temel Sağlık Hizmetleri Genel Müdürlüğü, Zoonotik Hastalıklar Daire Başkanlığı, Ankara, 2011.
• Bostancı S. Tulareminin kontrolü için Sağlık Bakanlığı’nca yapılan çalışmalar. III. Türkiye Zoonotok Hastalıklar Sempozyumu, 1-2 Kasım ,Ankara, Sempozyum Kitabı,s.19-22. Karadenizli A. Tularemi: Etken ve epidemiyoloji. III. Türkiye Zoo- notok Hastalıklar Sempozyumu, 1-2 Kasım 2010,Ankara, Sempozyum Kitabı,s.8-12.
• Tekin M,Çam OH, Acar G, kaytancı E, Hanege FM. Göztepe Tıp Dergisi 26(1):46-50, 2011
• Bıçakçı Z. Lenfadenopati Ayırıcı Tanısında Az Bilinen Bir Zoonoz: Orofarengeal Tularemi. 35. Ulusal Hematoloji Kongresi, 7-10 Ekim ; Antalya, Kongre Kitabı, s: 119-124. Eyibilen A, Ekinci A, Aladağ i. Servikal lenfadenit nedeni olarak tu- laremi. Dicle Tıp Dergisi,38(1) :76-78. Ulu Kılıç A, Kılıç S, Sencan I, Ciçek Şentürk G, Gürbüz Y, Tütüncü EE. A water-borne tularemia outbreak caused by Francisella tularensis subspecies holarctica in Central Anatolia region. Mikrobiyol Bul. 2011; (2):234-47.
• Sencan I, Sahin I, Kaya D, Oksuz S, Ozdemir D, Karabay O. An out- break of oropharyngeal tularemia with cervical adenopathy predomi- nantly in the left side. Yonsei Med J. 2009; 50 (1):50-4.
• Ozdemir D, Sencan I, Annakkaya AN, Karadenizli A, Guclu E, Sert E,et al. , Comparison of the 2000 and 2005 outbreaks of tularemia in the Duzce region of Turkey. Jpn J Infect Dis. 2007; 60(1):51-2.
• Leblebicioglu H, Esen S, Turan D, Tanyeri Y, Karadenizli A, Ziyagil F, Goral G. Outbreak of tularemia: case-control study and environmen- tal investigation in Turkey. Int J Infect Dis 2008; 12:265-269.
• Acicbe Ö,Aydın H, Doğancı L. Havza/ samsun bölgesi’nde tulare- mi endemisi: izlenen olgularının retrospektif yorumu. İnfeksiyon Der- gisi (Turkish Journal of Infection) 2007; 21 (2): 55-58.
• Karadenizli A, Gurcan S, Kolayli F, Vahaboglu H. Outbreak of tu- laraemia in Golcuk, Turkey in 2005: Report of 5 cases and an overview of the literature from Turkey. Scand J Infect Dis 2005;37(10):712-6.
• Gürcan Ş. Eskiocak M, Varol G, tularemi re-emerging in European part of Turkey after 60 years. Jpn J Infect Dis 2006; 59: 391-393.
• Helvacı S, Gedikoglu S, Akalın H, Oral HB. Tularemia in Bursa, Turkey: 205 cases in ten years. Eur J Epidemiol 2000; 16: 271-276.
• Willke A, Finke EJ, Grunow R, Sayan M, Erdogan S, Gedikoglu S.Evaluation of clinical, laboratory, and therapeutic features of 145 tu- laremia cases: the role of quinolones in oropharyngeal tularemia. AP- MIS 2008; 116(1): 66-73.
• Engin A, Altuntaş E, Cankorkmaz L, Kaya A, Elaldı N, Şimşek H. Sivas ilinde saptanan ilk tularemi salgını: 29 olgunun değerlendirilmesi. Klimik Dergisi 2011; 24(1): 17-23.
• Olgu sunumlarının giriş ve tartışma kısımları kısa-öz olmalı, kaynak sayısı 15 den az olmalıdır. Kısa raporlara özet yazılmamalı, en fazla 5 adet anahtar kelime, 10 kaynak, 1500 kelime, 2 tablo ve/veya şekil olma- lı ve yazının hemen sonunda sırasıyla yazar isimleri, ünvanları ve yazışma adresleri bulunmalıdır.
• Editöre mektup, dergide daha önce yayımlanmış yazılara bilimsel eleştiri yapmak, katkı sağlamak ya da orjinal bir ça- lışma olarak sunulmamış veya sunulamayacak bilgilerin paylaşılması amacıyla hazırlanmış en fazla 1000 kelimeden olu- şan, kısa-öz ve 6 dan az sayıda kaynağı olmalı özet içermemelidir.